# Outlook Therapeutics, Inc.: overview OTLK · Nasdaq · CIK 1649989 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Sep 30 Pages: [Overview](/companies/otlk.md) · [Financials](/companies/otlk/financials.md) · [Filings](/companies/otlk/filings.md) · [Insiders](/companies/otlk/insiders.md) Latest reported revenue: [−$91.8k](/filings/0001104659-25-123264.md) for Q4 FY2025, three months to 2025-09-30, from the 10-K filed Dec 19, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-25-123264). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-09-30) | Q1 FY2025 (2024-12-31) | Q2 FY2025 (2025-03-31) | Q3 FY2025 (2025-06-30) | Q4 FY2025 (2025-09-30) | Q1 FY2026 (2025-12-31) | Q2 FY2026 (2026-03-31) | Q3 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | [1,505](/filings/0001558370-25-011588.md) | [(91.8) d](/filings/0001104659-25-123264.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | [70.8%](/filings/0001104659-26-098415.md) | [1098.5% d](/filings/0001104659-25-123264.md) | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | [(1046.2%)](/filings/0001104659-26-098415.md) | [18863.9% d](/filings/0001104659-25-123264.md) | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | [(1338.8%)](/filings/0001104659-26-098415.md) | [14482.2% d](/filings/0001104659-25-123264.md) | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [0.72](/filings/0001104659-26-016554.md) | [(1.50)](/filings/0001104659-26-062632.md) | [(0.55)](/filings/0001104659-26-098415.md) | not reported | [(0.38)](/filings/0001104659-26-016554.md) | [(0.05)](/filings/0001104659-26-062632.md) | [(0.15)](/filings/0001104659-26-098415.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-09-30) | FY2022 (2022-09-30) | FY2023 (2023-09-30) | FY2024 (2024-09-30) | FY2025 (2025-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | [1,414](/filings/0001104659-25-123264.md) | | Gross margin | % | not reported | not reported | not reported | not reported | [4.0%](/filings/0001104659-25-123264.md) | | Operating margin | % | not reported | not reported | not reported | not reported | [(4744.3%)](/filings/0001104659-25-123264.md) | | Net margin | % | not reported | not reported | not reported | not reported | [(4416.2%)](/filings/0001104659-25-123264.md) | | Diluted EPS | $ per share | [(0.35)](/filings/0001558370-22-019036.md) | [(0.31)](/filings/0001558370-23-020000.md) | [(4.72)](/filings/0001558370-24-016491.md) | [(4.06)](/filings/0001104659-25-123264.md) | [(1.79)](/filings/0001104659-25-123264.md) | | Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/otlk/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.0m | 4,376,872 | | Added +2,409,712 | | [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $5.0m | 3,139,216 | | New +3,139,216 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.2m | 1,987,578 | | New +1,987,578 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.7m | 1,668,579 | | Added +1,191,108 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $2.3m | 1,425,270 | | New +1,425,270 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $2.0m | 1,245,868 | | Added +642,262 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $1.5m | 968,190 | | Added +834,106 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $1.1m | 661,664 | | Added +485,135 | | [GILPIN WEALTH MANAGEMENT, LLC](/funds/2058144.md) | 2026-06-30 | $882.5k | 555,000 | | Reduced −45,162 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $862.1k | 542,200 | Call | New +542,200 | ## Recent filings [All 833 filings](/companies/otlk/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 20:30 ET | [8-K](/filings/0001104659-26-112356.md) | 3.01 Delisting notice | 0001104659-26-112356 | | 2026-09-18 | 20:30 ET | [8-K](/filings/0001104659-26-108952.md) | 8.01 Other events | 0001104659-26-108952 | | 2026-08-27 | 20:11 ET | [8-K](/filings/0001104659-26-102446.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-102446 | | 2026-08-18 | 21:29 ET | [10-Q](/filings/0001104659-26-098415.md) | Quarterly report, period 2026-06-30 | 0001104659-26-098415 | | 2026-08-14 | 23:54 ET | [SCHEDULE 13D/A](/filings/0000899140-26-000895.md) | Ownership report, active investor, amended | 0000899140-26-000895 | | 2026-08-14 | 12:36 ET | [8-K](/filings/0001104659-26-096510.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-096510 | | 2026-08-14 | 12:00 ET | [8-K](/filings/0001104659-26-096478.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001104659-26-096478 | | 2026-08-12 | 20:01 ET | [8-K](/filings/0001104659-26-094848.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094848 | | 2026-07-24 | 21:01 ET | [8-K](/filings/0001104659-26-086685.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-086685 | | 2026-07-24 | 23:54 ET | [8-K](/filings/0001104659-26-086406.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-086406 | ## Latest annual report [Form 10-K for the fiscal year ended Sep 30, 2025](/filings/0001104659-25-123264.md), filed Dec 19, 2025. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1649989 - Tickers: OTLK - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.